Tolvaptan therapy for edema in patients with chronic kidney disease.
Zhou L, Xu Q, Xi X, Yu X, Li W.
Clin Nephrol · research support, non-u.s. gov't; journal article · DOI 10.5414/cn111365 PUBLIKATIONSREGISTRET
Gå till forskningen.
Publikationsdata från Europe PMC och PubMed. Följ källhänvisningar från ämnesregistret till originalpublikationerna.
Publikationer som ChEBI hänvisar till för tolvaptan. Visa hela publikationsregistret
En publikationsträff är inte en slutsats. Publikationslistan visar bibliografiska uppgifter. Eventuella forskningsutdrag visas separat med originalunderlag. En källhänvisning visar inte i sig effekt, dosering eller säkerhet.
Publikationer i urvalet
36 träffarClinical efficacy of tolvaptan in acute decompensated heart failure patients with severe aortic stenosis and atrial fibrillation: a sub-analysis from the LOHAS registry.
Murakami T, Watanabe Y, Nakamura N, Natsumeda M, Ohno Y, Nakazawa G, Ikari Y, Kataoka A, Nishihata Y, Hayashida K, Yamamoto M, Tanaka J, Jujo K, Izumo M, Mizutani K, Kozuma K.
Heart Vessels · multicenter study; journal article · DOI 10.1007/s00380-024-02397-3An Electronic Health Record-Integrated Application for Standardizing Care and Monitoring Patients With Autosomal Dominant Polycystic Kidney Disease Enrolled in a Tolvaptan Clinic: Design and Implementation Study.
Chedid M, Chebib FT, Dahlen E, Mueller T, Schnell T, Gay M, Hommos M, Swaminathan S, Garg A, Mao M, Amberg B, Balderes K, Johnson KF, Bishop A, Vaughn JK, Hogan M, Torres V, Chaudhry R, Zoghby Z.
JMIR Med Inform · research-article; journal article · DOI 10.2196/50164Comparative Safety and Effectiveness of Urea and Tolvaptan for the Management of Hyponatremia.
Scalla PA, Palma SM, Dittmar E, Zamora FJ, Trimino E.
J Pharm Pract · comparative study; multicenter study; journal article · DOI 10.1177/08971900241247617Long-term effectiveness and safety of tolvaptan in autosomal dominant polycystic kidney disease.
Cantarelli L, Gutiérrez Valencia M, Leache Alegria L, Sainz Fernandez LC, Erviti Lopez J, Gutiérrez Nicolas F, Nazco Casariego GJ.
Med Clin (Barc) · journal article; observational study · DOI 10.1016/j.medcli.2024.01.026Visceral Adiposity and Progression of ADPKD: A Cohort Study of Patients From the TEMPO 3:4 Trial.
Nowak KL, Moretti F, Bussola N, Steele CN, Gregory AV, Kline TL, Ramanathan S, Trapletti G, Furlanello C, McCormick L, Chonchol M.
Am J Kidney Dis · research support, non-u.s. gov't; research-article; randomized controlled trial; journal article; research support, n.i.h., extramural · DOI 10.1053/j.ajkd.2024.02.014A secondary analysis of concurrent use of metformin and tolvaptan in ADPKD tolvaptan trials.
Stanley IK, Palma AM, Viecelli AK, Johnson DW, Hawley CM, Staatz CE, Mallett AJ.
J Nephrol · letter · DOI 10.1007/s40620-024-01906-xLong-Residence Time Peptide Antagonist for the Vasopressin V<sub>2</sub> Receptor to Treat Autosomal Dominant Polycystic Kidney Disease.
Xiong X, Wang N, Zhang Y, Zhao W, Pang N, Fu K, Zhou N, Zhou X, Guo D.
J Med Chem · research support, non-u.s. gov't; journal article · DOI 10.1021/acs.jmedchem.4c00217Additional renoprotective effect of the SGLT2 inhibitor dapagliflozin in a patient with ADPKD receiving tolvaptan treatment.
Minatoguchi S, Hayashi H, Umeda R, Koide S, Hasegawa M, Tsuboi N.
CEN Case Rep · journal article; case reports; case-report · DOI 10.1007/s13730-024-00859-1Renal ultrasonography predicts worsening renal function in patients with heart failure under tolvaptan administration.
Tanaka N, Furukawa Y, Maeda T, Ishihara H, Dan K, Teramura M, Ichihashi K, Takase T, Takahashi Y, Tsuzura D, Shinoda A, Fujii M, Okada H, Itabashi F, Teramoto T.
ESC Heart Fail · research-article; journal article · DOI 10.1002/ehf2.14740Evaluation of the Renal and Cardiovascular Effects of Long-Term Tolvaptan Treatment in Autosomal Dominant Polycystic Kidney Disease.
Demiray A, Ozan R, Özaytürk SG, İmamoğlu H, Zararsız G, Sipahioğlu MH, Tokgöz B, Elçik D, Koçyiğit İ.
Cardiorenal Med · journal article · DOI 10.1159/000538098Initial eGFR Changes Predict Response to Tolvaptan in ADPKD.
Mochizuki T, Matsukawa M, Tanaka T, Jiang H.
Kidney360 · letter; research support, non-u.s. gov't; research-article · DOI 10.34067/kid.0000000000000404Tolvaptan and Number Needed to Harm in Autosomal Dominant Polycystic Kidney Disease.
Betts KA, Nunna S, Kumar R, Nie X, Fernandes AW.
Kidney Med · brief-report; journal article · DOI 10.1016/j.xkme.2024.100802Long-Term Effects of Tolvaptan in Autosomal Dominant Polycystic Kidney Disease: Predictors of Treatment Response and Safety over 6 Years of Continuous Therapy.
Yamazaki M, Kawano H, Miyoshi M, Kimura T, Takahashi K, Muto S, Horie S.
Int J Mol Sci · research-article; journal article · DOI 10.3390/ijms25042088Preliminary Report of Intravenous Tolvaptan Sodium Phosphate (Samtas<sup>®</sup>) Treatment in Decompensated Heart Failure.
Nakamura M, Imamura T, Kinugawa K.
J Clin Med · research-article; journal article · DOI 10.3390/jcm13030720Pharmacokinetics, pharmacodynamics and safety of 15 mg-tolvaptan administered orally for 7 consecutive days to Chinese patients with child-Pugh B cirrhosis.
Liu H, Wang Y, Liu T, Chen Y, Zheng X, Liu M, Zhao Q, Zeng M, Jiang J, Mao Y, Hu P.
Front Pharmacol · research-article; journal article · DOI 10.3389/fphar.2024.1324299Treatment for patients with autosomal dominant polycystic kidney disease in the chronic kidney disease without kidney replacement therapy in real-world clinical practice: a descriptive retrospective cohort study.
Sakoda K, Mizuno K, Seki T, Shinkawa K, Kawai Y, Hayashi A, Yoshida S, Takeuchi M, Yanagita M, Kawakami K.
Ann Clin Epidemiol · research-article; journal article · DOI 10.37737/ace.24006Case report: Twice-daily tolvaptan dosing regimen in a challenging case of hyponatremia due to SIAD.
Arecco A, Demontis D, Della Sala L, Musso N, Gay S, Boschetti M, Ferone D, Gatto F.
Front Endocrinol (Lausanne) · journal article; case reports; case-report · DOI 10.3389/fendo.2023.1309657Real-life use of tolvaptan in ADPKD: a retrospective analysis of a large Canadian cohort.
Calvaruso L, Yau K, Akbari P, Nasri F, Khowaja S, Wang B, Haghighi A, Khalili K, Pei Y.
Sci Rep · research-article; journal article · DOI 10.1038/s41598-023-48638-9Uric acid levels with tolvaptan treatment for syndrome of inappropriate antidiuretic hormone secretion.
Nagamine T.
Endocrine · letter; comment · DOI 10.1007/s12020-023-03612-3Vasopressin V2 receptor, tolvaptan, and ERK1/2 phosphorylation in the renal collecting duct.
Khan S, Raghuram V, Chen L, Chou CL, Yang CR, Khundmiri SJ, Knepper MA.
Am J Physiol Renal Physiol · research support, n.i.h., intramural; research support, non-u.s. gov't; research-article; journal article · DOI 10.1152/ajprenal.00124.2023Effect of early administration of tolvaptan on pleural effusion post-hepatectomy.
Iida H, Maehira H, Mori H, Nitta N, Maekawa T, Takebayashi K, Kaida S, Miyake T, Tani M.
Langenbecks Arch Surg · journal article · DOI 10.1007/s00423-023-03136-4Tolvaptan-related toxicoderma.
Rivas Oural A, Bande Fernández JJ, Morán Fernández LF, Requena López S, Vivanco Allende B, Astudillo Cortés E.
Nefrologia (Engl Ed) · letter; case reports · DOI 10.1016/j.nefroe.2023.01.001Effect of tolvaptan on hyponatremia in a dog with syndrome of inappropriate secretion of antidiuretic hormone.
Yamamoto H, Kimura K, Horikirizono H, Tamura Y, Kambayashi S, Baba K, Okuda M, Mizuno T, Igase M.
J Vet Med Sci · journal article; case reports; case-report · DOI 10.1292/jvms.23-0243Tolvaptan for water retention in heart failure: a systematic review.
Pan Y, Li H, Gao J, Mi Z, Chen H, Li Y.
Syst Rev · research support, non-u.s. gov't; research-article; systematic review; journal article · DOI 10.1186/s13643-023-02293-3Tolvaptan and urea in paediatric hyponatraemia.
Veligratli F, Alexandrou D, Shah S, Amin R, Dattani M, Gan HW, Famuboni A, Lopez-Garcia C, Trompeter R, Bockenhauer D.
Pediatr Nephrol · review; journal article · DOI 10.1007/s00467-023-06091-wTolvaptan for the treatment of the syndrome of inappropriate antidiuresis (SIAD).
Tzoulis P, Kaltsas G, Baldeweg SE, Bouloux PM, Grossman AB.
Ther Adv Endocrinol Metab · review-article; review; journal article · DOI 10.1177/20420188231173327Renoprotection by long-term low-dose tolvaptan in patients with heart failure and hyponatremia.
Oka T, Hamano T, Ohtani T, Doi Y, Shimada K, Matsumoto A, Yamaguchi S, Hashimoto N, Senda M, Sakaguchi Y, Matsui I, Nakamoto K, Sera F, Hikoso S, Sakata Y, Isaka Y.
ESC Heart Fail · research-article; journal article · DOI 10.1002/ehf2.13507Long-Term Benefits of Treatment with Tolvaptan in Patients with Autosomal Dominant Polycystic Kidney Disease.
Shimoda N, Ikeda M, Yan T, Kawasaki S, Hirama A, Kashiwagi T, Sakai Y.
J Nippon Med Sch · journal article · DOI 10.1272/jnms.jnms.2022_89-303Effect of oral tolvaptan for 1 year in patients with functional mitral regurgitation.
Nagura F, Kataoka A, Ishibashi R, Mitsui M, Hioki H, Kuwabara M, Uno K, Watanabe Y, Yokoyama N, Kozuma K.
Heart Vessels · journal article · DOI 10.1007/s00380-021-01934-8